Catch up on the top radiology content of the past week.
|Articles|April 15, 1998
ATL names new division SonoSight
ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound
Advertisement
ATL Ultrasound has announced that the distribution date for its handheld division took place on April 6 (SCAN 3/18/98). The new company, called SonoSight, will trade on the NASDAQ National Market under the ticker symbol SONO. ATL Ultrasound shareholders of record on March 30 will receive one share of SonoSight for every three shares held of ATL.
SonoSight has filed a 510(k) premarket notification for its first product, with commercial launch anticipated in 1999, according to ATL. A prototype of the first handheld system, targeted for use in women's healthcare, is expected within a few months. Other models are being developed for internal and emergency medical use.
In other SonoSight developments, Kevin Goodwin has been tapped as president and CEO of the company, with Kirby Cramer serving as chairman. Cramer is a member of the ATL board of directors and president of investment firm Keystone Capital Company.
Advertisement
Related to this article
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.
Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?
In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.
Catch up on the most-well viewed radiology content in September 2026.
The BiPASS program, which combines 68Ga PSMA PET imaging with prostate MRI prior to the use of prostate biopsy, is slated to be evaluated in an impending phase 3 trial.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging's Weekly Scan: September 27 — October 3
2
The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 1
3
Raising Questions on the Prognostic Value of Fractional Flow Reserve from CCTA
4
Emerging Research Insights and New Advances in Neuroradiology
5